These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27183782)

  • 21. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
    Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
    PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
    Kim H; Kim M; Oh K; Lee S; Lim S; Lee S; Kim YH; Suh KH; Min KH
    Eur J Med Chem; 2023 Oct; 258():115584. PubMed ID: 37356344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
    Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.
    Kim SR; Kim DH; Park SH; Kim YS; Kim CH; Ha TY; Yang J; Rhee JK
    J Diabetes Res; 2013; 2013():269569. PubMed ID: 24386644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
    Lasalle M; Hoguet V; Hennuyer N; Leroux F; Piveteau C; Belloy L; Lestavel S; Vallez E; Dorchies E; Duplan I; Sevin E; Culot M; Gosselet F; Boulahjar R; Herledan A; Staels B; Deprez B; Tailleux A; Charton J
    J Med Chem; 2017 May; 60(10):4185-4211. PubMed ID: 28414465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-OMe-lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activity.
    Drzazga A; Sowińska A; Krzemińska A; Okruszek A; Paneth P; Koziołkiewicz M; Gendaszewska-Darmach E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):91-103. PubMed ID: 29079451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.
    Zhao J; Zhao Y; Hu Y; Peng J
    Cell Mol Biol Lett; 2021 Jul; 26(1):32. PubMed ID: 34233623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.